About Medio Labs
We're building the future of clinical diagnostic services.
Medio Labs is applying the very latest DNA engineering and sequencing technologies to revolutionize clinical diagnostic testing. The company's innovations are designed to radically expand access to the latest diagnostic technology with the goal of driving a wholesale shift from treating health crises after they occur, to regular advanced screening that prevents healthcare crises from occurring in the first place.
Year we were founded
Clinical tests processed in 2022
Number of diseases detected
We are a diverse team of creative innovators who revel in making science fiction into real working technology with global impact.
At Medio Labs, we are driving a revolution in healthcare designed to massively reduce the cost of state-of-the-art clinical diagnostic testing and expand global access to quality care.
The company is applying deep expertise in clinical diagnostic assay design that leverages the latest next-generation sequencing platforms along with molecular bar codes written in RNA and attached chemically to patient samples to increase the scale and reduce the cost of quantifying multiple pathogens in every individual patient sample.
The impact of being able to test for multiple diseases that might have any number of symptoms in common using Just One Test is profound. Testing costs are dramatically reduced, Turn-around times are accelerated even in pandemic surges. Time to validated course of treatment is reduced, and patient outcomes improved.
Medio Labs Leadership
Our team of renowned experts offer their professional services to help your organization understand, plan for, and manage all aspects of the pandemic from general analytics of the pandemic and your organization’s pandemic response to facility risk assessment and upgrades, to pandemic operations. Medio Labs experts will work to design the best system for your needs and regularly examine your data to help you identify hot spots and minimize COVID-19 infection rates, outbreaks, and shut-downs.